Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:LIFE

aTyr Pharma (LIFE) Stock Price, News & Analysis

aTyr Pharma logo

About aTyr Pharma Stock (NASDAQ:LIFE)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$1.57
$2.07
52-Week Range
N/A
Volume
269,400 shs
Average Volume
514,103 shs
Market Capitalization
$131.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

Receive LIFE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for aTyr Pharma and its competitors with MarketBeat's FREE daily newsletter.

LIFE Stock News Headlines

Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
Is aTyr Pharma (ATYR) The Hot Biotech Stock Under $5?
aTyr Pharma (ATYR) Receives a Buy from Wells Fargo
aTyr Pharma director buys $15K in common stock
See More Headlines

LIFE Stock Analysis - Frequently Asked Questions

aTyr Pharma, Inc. (NASDAQ:LIFE) announced its quarterly earnings results on Thursday, May, 2nd. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.24) by $0.01. The biotechnology company had revenue of $0.24 million for the quarter, compared to the consensus estimate of $0.11 million.

Shares of aTyr Pharma reverse split on the morning of Monday, July 1st 2019. The 1-14 reverse split was announced on Friday, June 28th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 28th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

aTyr Pharma (LIFE) raised $76 million in an IPO on Thursday, May 7th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Citigroup served as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that aTyr Pharma investors own include Tesla (TSLA), Plug Power (PLUG), Meta Platforms (META), NVIDIA (NVDA), SCYNEXIS (SCYX), Ford Motor (F) and NIO (NIO).

Company Calendar

Last Earnings
5/02/2024
Today
5/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:LIFE
Employees
56
Year Founded
2005

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$50.39 million
Pretax Margin
-9,172.11%

Debt

Sales & Book Value

Annual Sales
$350,000.00
Price / Cash Flow
N/A
Book Value
$1.54 per share
Price / Book
N/A

Miscellaneous

Free Float
66,458,000
Market Cap
$131.12 million
Optionable
Optionable
Beta
1.19

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:LIFE) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners